

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* <u>Parsey Merdad</u> (Last) (First) (Middle) <u>GILEAD SCIENCES, INC.</u> <u>333 LAKESIDE DRIVE</u> (Street) <u>FOSTER CITY CA 94404</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>GILEAD SCIENCES INC [GILD]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>02/15/2021</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Medical Officer</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/15/2021		A	V	364 ⁽¹⁾	A	\$56.8565 ⁽²⁾	12,263	D	
Common Stock	03/10/2021		M		3,455	A	⁽³⁾	15,718	D	
Common Stock	03/10/2021		F		1,639	D	\$63.91	14,079	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	⁽³⁾	03/10/2021		M			3,455	⁽⁴⁾	⁽⁴⁾	Common Stock	3,455	⁽³⁾	20,564	D	
Restricted Stock Unit	⁽³⁾	03/10/2021		A		16,625		⁽⁵⁾	⁽⁵⁾	Common Stock	16,625	⁽³⁾	37,189	D	
Non-qualified Stock Option (Right to Buy)	\$63.91	03/10/2021		A		96,760		⁽⁶⁾	03/10/2031	Common Stock	96,760	\$0	96,760	D	

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c).
2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's stock on February 15, 2021.
3. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
4. The restricted stock units have a four- year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.
5. The restricted stock units have a four-year vesting schedule. 25% will vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
6. The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

/s/ Amy Kim by Power of
Attorney for Merdad Parsey 03/12/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.